Author:
Yu Jing-ze,Wen Jing,Ying Yi,Yin Wen,Zhang Si-qi,Pang Wen-ling,Wang Cui,Bian Yao,Yuan Jia-li,Yan Jin-yuan,Yang Zhong-shan
Funder
National Natural Science Foundation of China
Yunnan Provincial Science and Technology Department
Subject
Pharmacology,General Medicine
Reference47 articles.
1. Pulmonary fibrosis, Part I: epidemiology, pathogenesis, and diagnosis;Meyer;Expert Rev. Respir. Med.,2017
2. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am. J. Respir. Crit. Care Med.,2011
3. Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema;Cornwell;Biomark.: Biochem. Indic. Expo. Response Susceptibility Chem.,2019
4. Idiopathic pulmonary fibrosis: epithelial-mesenchymal interactions and emerging therapeutic targets;Hewlett;Matrix Biol.: J. Int. Soc. Matrix Biol.,2018
5. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial;King;Lancet,2009